Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
43 hedge funds and large institutions have $48.1M invested in Merrimack Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
5% more funds holding
Funds holding: 41 → 43 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
3% less capital invested
Capital invested by funds: $49.5M → $48.1M (-$1.4M)
59% less call options, than puts
Call options by funds: $117K | Put options by funds: $283K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$548K |
| 2 |
NM
Newtyn Management
New York
|
+$250K |
| 3 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$153K |
| 4 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$112K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$91.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$143K |
| 2 |
RCM
Radnor Capital Management
Wayne,
Pennsylvania
|
-$84K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.1K |
| 4 |
Two Sigma Investments
New York
|
-$32.8K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$32.6K |
MACK Hedge Fund Activity: Q2 2022 in Review
43 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2022, worth a combined $48.1M — down 2.8% from $49.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MACK positions and 1 closed out — a net gain of 2 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Western Standard LLC, adding an estimated $548K. The largest seller was Nantahala Capital Management, cutting an estimated $143K.
- 43 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2022, up from 41 in Q1 2022.
- Funds reported $48.1M of Merrimack Pharmaceuticals, Inc. stock for Q2 2022, down 2.8% quarter-over-quarter.
- 3 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2022 and 1 closed out, a net change of +2 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2022 was Western Standard LLC, an estimated $548K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2022 was Nantahala Capital Management, an estimated $143K sold.
Based on aggregated 13F filings for Q2 2022.